Cabozantinib capsules (COMETRIQ) are approved for the treatment of patients with
progressive metastatic medullary thyroid cancer. Cabozantinib tablets are investigational
drug products considered to be potentially preferred pharmaceutical dosing forms. Two
phase I open-label single-dose studies in healthy individuals were carried out to
characterize the plasma pharmacokinetics of cabozantinib capsule and tablet formulations:
a two-way crossover bioequivalence study (n= 77) comparing the tablet formulation and the …